General Comments / Chat, page-7616

The one thing that people who are selling now are missing is -
— we will be starting the cardio protection trial this year. It might very well coincide with the new IV formulation. If it’s being done in partnership with a BP, it will no doubt re-rate the stock.
Market also loves anticipation of clinical results, specially when the potential is shown via the triangle report, in billions just for a small segment of breast cancer. If the KOLs and scientists research on the report is anything to go by, the uptake and participation of this trial will be fast track and quite possible we start getting open label results at this next time year. It is an absolute game changer that a lot would be keen to participate.

In the meantime, we are also getting clinical results from sheba2 this year.
I anticipate some re-rate to upside this year, and a really big jump next year due to the readings from clinical results, partnership and subsequent buyout. Time to take advantage of CGT is right now. IMO.